{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:00Z","timestamp":1790963580695,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.semcancer.2013.09.001","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T23:01:50Z","timestamp":1379718110000},"page":"410-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":188,"special_numbering":"PA","title":["B-cell receptor signaling as a driver of lymphoma development and evolution"],"prefix":"10.1016","volume":"23","author":[{"given":"Carsten U.","family":"Niemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"March (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"October (16)","key":"10.1016\/j.semcancer.2013.09.001_bib0010","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J Clin Oncol"},{"issue":"August (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"December (12)","key":"10.1016\/j.semcancer.2013.09.001_bib0025","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3109\/10428194.2012.695781","article-title":"Targeting the B cell receptor pathway in chronic lymphocytic leukemia","volume":"53","author":"Davids","year":"2012","journal-title":"Leukemia Lymphoma"},{"issue":"December (13)","key":"10.1016\/j.semcancer.2013.09.001_bib0030","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood.V98.13.3745","article-title":"The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis","volume":"98","author":"Quinn","year":"2001","journal-title":"Blood"},{"issue":"July (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"issue":"November (20)","key":"10.1016\/j.semcancer.2013.09.001_bib0040","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2012-05-427534","article-title":"Self-antigen recognition by follicular lymphoma B-cell receptors","volume":"120","author":"Sachen","year":"2012","journal-title":"Blood"},{"issue":"September (7415)","key":"10.1016\/j.semcancer.2013.09.001_bib0045","first-page":"309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Duhren-von","year":"2012","journal-title":"Nature"},{"issue":"June (23)","key":"10.1016\/j.semcancer.2013.09.001_bib0050","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood-2012-08-447904","article-title":"Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells","volume":"121","author":"Zwick","year":"2013","journal-title":"Blood"},{"issue":"May (19)","key":"10.1016\/j.semcancer.2013.09.001_bib0055","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"issue":"March (5870)","key":"10.1016\/j.semcancer.2013.09.001_bib0060","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"April (13)","key":"10.1016\/j.semcancer.2013.09.001_bib0065","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.09.001_bib0070","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"October","author":"Advani","year":"2012","journal-title":"J Clin Oncol"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0075","first-page":"904","article-title":"Interim results of an international, multicenter, phase 2 study of Bruton's tyrosine kinase (btk) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up","volume":"120","author":"Wang","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0080","first-page":"2716","article-title":"The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed\/refractory ABC DLBCL","volume":"118","author":"Staudt","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0085","first-page":"2899","article-title":"Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death","volume":"120","author":"Farooqui","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"July (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"June (15_suppl)","key":"10.1016\/j.semcancer.2013.09.001_bib0095","first-page":"6631","article-title":"Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia","volume":"29","author":"Coutre","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0100","first-page":"185","article-title":"In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients","volume":"120","author":"Herman","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"1\u20133","key":"10.1016\/j.semcancer.2013.09.001_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/IR:36:1:27","article-title":"From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion","volume":"36","author":"Borghesi","year":"2006","journal-title":"Immunol Res"},{"issue":"September (7314)","key":"10.1016\/j.semcancer.2013.09.001_bib0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nature09357","article-title":"Oligomeric organization of the B-cell antigen receptor on resting cells","volume":"467","author":"Yang","year":"2010","journal-title":"Nature"},{"issue":"May (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0115","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1084\/jem.20092123","article-title":"Antigen affinity discrimination is an intrinsic function of the B cell receptor","volume":"207","author":"Liu","year":"2010","journal-title":"J Exp Med"},{"issue":"March (6214)","key":"10.1016\/j.semcancer.2013.09.001_bib0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/338383b0","article-title":"Antigen receptor tail clue","volume":"338","author":"Reth","year":"1989","journal-title":"Nature"},{"issue":"February (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coi.2011.12.010","article-title":"Role of ITAM signaling module in signal integration","volume":"24","author":"Bezbradica","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"March (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ni893","article-title":"Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development","volume":"4","author":"Saijo","year":"2003","journal-title":"Nat Immunol"},{"issue":"November (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0135","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/1074-7613(95)90126-4","article-title":"Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice","volume":"3","author":"Nishizumi","year":"1995","journal-title":"Immunity"},{"issue":"October (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"issue":"August (33)","key":"10.1016\/j.semcancer.2013.09.001_bib0145","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0150","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1021\/ja208518u","article-title":"Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes","volume":"134","author":"Shi","year":"2012","journal-title":"J Am Chem Soc"},{"issue":"March (12)","key":"10.1016\/j.semcancer.2013.09.001_bib0155","first-page":"2264","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia","volume":"121","author":"Ten","year":"2013","journal-title":"Blood"},{"issue":"January (7277)","key":"10.1016\/j.semcancer.2013.09.001_bib0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"May (9)","key":"10.1016\/j.semcancer.2013.09.001_bib0165","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"June (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"January (9403)","key":"10.1016\/j.semcancer.2013.09.001_bib0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukaemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"issue":"November (6554)","key":"10.1016\/j.semcancer.2013.09.001_bib0180","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/378303a0","article-title":"Syk tyrosine kinase required for mouse viability and B-cell development","volume":"378","author":"Cheng","year":"1995","journal-title":"Nature"},{"issue":"November (6554)","key":"10.1016\/j.semcancer.2013.09.001_bib0185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/378298a0","article-title":"Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk","volume":"378","author":"Turner","year":"1995","journal-title":"Nature"},{"issue":"May (19)","key":"10.1016\/j.semcancer.2013.09.001_bib0190","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1074\/jbc.270.19.11590","article-title":"Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha\/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation","volume":"270","author":"Rowley","year":"1995","journal-title":"J Biol Chem"},{"issue":"May (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0195","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/13543784.2011.570329","article-title":"The Syk kinase as a therapeutic target in leukemia and lymphoma","volume":"20","author":"Efremov","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semcancer.2013.09.001_bib0200","article-title":"Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"February","author":"Herman","year":"2013","journal-title":"Leukemia"},{"issue":"February (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","article-title":"An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"July (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0210","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"March (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances","volume":"442","author":"So","year":"2012","journal-title":"Biochem J"},{"issue":"April (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0220","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","article-title":"Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation","volume":"23","author":"Baracho","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"October (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0225","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"issue":"134","key":"10.1016\/j.semcancer.2013.09.001_bib0230","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal"},{"issue":"February (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrm2328","article-title":"Membrane recognition by phospholipid-binding domains","volume":"9","author":"Lemmon","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"March (9)","key":"10.1016\/j.semcancer.2013.09.001_bib0240","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2009-09-242719","article-title":"Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression","volume":"115","author":"Ghosh","year":"2010","journal-title":"Blood"},{"issue":"February (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0245","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood-2010-09-305649","article-title":"The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy","volume":"117","author":"Ghosh","year":"2011","journal-title":"Blood"},{"issue":"August (17)","key":"10.1016\/j.semcancer.2013.09.001_bib0250","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/emboj.2011.251","article-title":"The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85","volume":"30","author":"Oellerich","year":"2011","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.semcancer.2013.09.001_bib0255","doi-asserted-by":"crossref","first-page":"e31829","DOI":"10.1371\/journal.pone.0031829","article-title":"Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor","volume":"7","author":"Miyazaki","year":"2012","journal-title":"PLoS ONE"},{"issue":"March (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0260","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1074\/jbc.274.11.7489","article-title":"The SH2 domain-containing inositol 5\u2019-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling","volume":"274","author":"Gupta","year":"1999","journal-title":"J Biol Chem"},{"issue":"August (8)","key":"10.1016\/j.semcancer.2013.09.001_bib0265","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/14728222.2011.585971","article-title":"Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man","volume":"15","author":"Hendriks","year":"2011","journal-title":"Expert Opin Ther Targets"},{"issue":"June (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0270","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"BRUTON OC","year":"1952","journal-title":"Pediatrics"},{"issue":"September (36)","key":"10.1016\/j.semcancer.2013.09.001_bib0275","doi-asserted-by":"crossref","first-page":"37651","DOI":"10.1074\/jbc.M311985200","article-title":"Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker","volume":"279","author":"Humphries","year":"2004","journal-title":"J Biol Chem"},{"issue":"December (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbrc.2008.09.055","article-title":"Crystal structure of the Bruton's tyrosine kinase PH domain with phosphatidylinositol","volume":"377","author":"Murayama","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"April (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"July (29)","key":"10.1016\/j.semcancer.2013.09.001_bib0290","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J Immunol"},{"issue":"June (12)","key":"10.1016\/j.semcancer.2013.09.001_bib0300","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1084\/jem.20020408","article-title":"Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha","volume":"195","author":"Saijo","year":"2002","journal-title":"J Exp Med"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0305","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"issue":"November (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0310","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/156652405774641034","article-title":"Mammalian target of rapamycin as a therapeutic target in leukemia","volume":"5","author":"Giles","year":"2005","journal-title":"Curr Mol Med"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0315","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2002-01-0189","article-title":"G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin","volume":"101","author":"Decker","year":"2003","journal-title":"Blood"},{"issue":"March (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0305-7372(81)80006-0","article-title":"New antitumor substances of natural origin","volume":"8","author":"Douros","year":"1981","journal-title":"Cancer Treat Rev"},{"issue":"August (5022)","key":"10.1016\/j.semcancer.2013.09.001_bib0325","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"issue":"April (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0330","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"March (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00277-008-0582-9","article-title":"A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL","volume":"88","author":"Decker","year":"2009","journal-title":"Ann Hematol"},{"issue":"May (9)","key":"10.1016\/j.semcancer.2013.09.001_bib0340","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/cncr.25005","article-title":"The treatment of recurrent\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation","volume":"116","author":"Zent","year":"2010","journal-title":"Cancer"},{"issue":"August (23)","key":"10.1016\/j.semcancer.2013.09.001_bib0345","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"November (31)","key":"10.1016\/j.semcancer.2013.09.001_bib0350","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"issue":"July (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0355","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"issue":"February (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0360","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"issue":"February (4)","key":"10.1016\/j.semcancer.2013.09.001_bib0365","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.4049\/jimmunol.0902334","article-title":"Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition","volume":"184","author":"Liu","year":"2010","journal-title":"J Immunol"},{"issue":"November (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0370","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/ni.2116","article-title":"Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments","volume":"12","author":"Chaturvedi","year":"2011","journal-title":"Nat Immunol"},{"issue":"November (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0375","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.immuni.2011.10.011","article-title":"Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy","volume":"35","author":"O\u2019Neill","year":"2011","journal-title":"Immunity"},{"issue":"December (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0380","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbrc.2007.09.100","article-title":"Interdomain A is crucial for ITAM-dependent and -independent regulation of Syk","volume":"364","author":"Adachi","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"September (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-065X.2010.00936.x","article-title":"Molecular underpinning of B-cell anergy","volume":"237","author":"Yarkoni","year":"2010","journal-title":"Immunol Rev"},{"issue":"August (8)","key":"10.1016\/j.semcancer.2013.09.001_bib0390","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/13543784.2011.590130","article-title":"Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies","volume":"20","author":"Ysebaert","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"May (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0395","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3109\/10428194.2011.634041","article-title":"Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells","volume":"53","author":"Liffraud","year":"2012","journal-title":"Leukemia Lymphoma"},{"issue":"March (12)","key":"10.1016\/j.semcancer.2013.09.001_bib0400","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","article-title":"PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia","volume":"113","author":"Holler","year":"2009","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0405","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2012.12.003","article-title":"Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo","volume":"23","author":"Lutzny","year":"2013","journal-title":"Cancer Cell"},{"issue":"January (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0410","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/MCB.00850-12","article-title":"A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival","volume":"33","author":"Chan","year":"2013","journal-title":"Mol Cell Biol"},{"issue":"January (6970)","key":"10.1016\/j.semcancer.2013.09.001_bib0415","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature02273","article-title":"Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO","volume":"427","author":"Zhou","year":"2004","journal-title":"Nature"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0420","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.20757","article-title":"Preclinical assessment of curcumin as a potential therapy for B-CLL","volume":"82","author":"Everett","year":"2007","journal-title":"Am J Hematol"},{"issue":"September (17)","key":"10.1016\/j.semcancer.2013.09.001_bib0425","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-12-0779","article-title":"Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma","volume":"18","author":"Fabre","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"February (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0430","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0435","first-page":"867","article-title":"P B S-1086, a \u201cPan-Rel\u201d inhibitor, decreases viability of chronic lymphocytic leukemia cells","volume":"120","author":"Tudhope","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"February (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0440","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","article-title":"Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities","volume":"117","author":"Marcucci","year":"2011","journal-title":"Blood"},{"issue":"March (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0445","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2036.2005.02395.x","article-title":"Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection","volume":"21","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"May (18)","key":"10.1016\/j.semcancer.2013.09.001_bib0450","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199405053301803","article-title":"Helicobacter pylori infection and gastric lymphoma","volume":"330","author":"Parsonnet","year":"1994","journal-title":"N Engl J Med"},{"issue":"September (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0455","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9440(10)62052-4","article-title":"The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma","volume":"167","author":"Mueller","year":"2005","journal-title":"Am J Pathol"},{"issue":"October (8)","key":"10.1016\/j.semcancer.2013.09.001_bib0460","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest"},{"issue":"November (9)","key":"10.1016\/j.semcancer.2013.09.001_bib0465","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2004-01-0132","article-title":"Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia","volume":"104","author":"Tobin","year":"2004","journal-title":"Blood"},{"issue":"August (4)","key":"10.1016\/j.semcancer.2013.09.001_bib0470","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia","volume":"200","author":"Messmer","year":"2004","journal-title":"J Exp Med"},{"issue":"February (8)","key":"10.1016\/j.semcancer.2013.09.001_bib0475","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"issue":"March (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0480","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2004-05-1715","article-title":"ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia","volume":"105","author":"Chen","year":"2005","journal-title":"Blood"},{"issue":"March (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0485","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"issue":"January (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0490","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"December (13)","key":"10.1016\/j.semcancer.2013.09.001_bib0495","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","article-title":"Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA","volume":"112","author":"Chu","year":"2008","journal-title":"Blood"},{"issue":"April (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0500","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","article-title":"A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies","volume":"111","author":"Lanemo","year":"2008","journal-title":"Blood"},{"issue":"March (10)","key":"10.1016\/j.semcancer.2013.09.001_bib0505","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood-2011-08-374058","article-title":"Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen","volume":"119","author":"Steininger","year":"2012","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J Exp Med"},{"issue":"May (10)","key":"10.1016\/j.semcancer.2013.09.001_bib0515","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2006-11-056648","article-title":"Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status","volume":"109","author":"Mockridge","year":"2007","journal-title":"Blood"},{"issue":"July (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0520","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"issue":"June (26)","key":"10.1016\/j.semcancer.2013.09.001_bib0850","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1182\/blood-2011-02-336164","article-title":"B-cell receptors and heavy chain diseases: guilty by association?","volume":"117","author":"Corcos","year":"2011","journal-title":"Blood"},{"issue":"May (9)","key":"10.1016\/j.semcancer.2013.09.001_bib0525","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/cncr.25755","article-title":"B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia","volume":"117","author":"Binder","year":"2011","journal-title":"Cancer"},{"issue":"August (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0530","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2007-12-127688","article-title":"BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells","volume":"112","author":"Guarini","year":"2008","journal-title":"Blood"},{"issue":"March (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11899-011-0104-z","article-title":"Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia","volume":"7","author":"Burger","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.semcancer.2013.09.001_bib0540","doi-asserted-by":"crossref","first-page":"e2012067","DOI":"10.4084\/mjhid.2012.067","article-title":"Emerging strategies for targeting the B-cell receptor pathway in CLL","volume":"4","author":"Efremov","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"December (24)","key":"10.1016\/j.semcancer.2013.09.001_bib0545","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"issue":"September (15)","key":"10.1016\/j.semcancer.2013.09.001_bib0550","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","article-title":"Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases","volume":"118","author":"Hadzidimitriou","year":"2011","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0555","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.09.001_bib0560","article-title":"Clues to pathogenesis of Waldenstrom macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors","volume":"April","author":"Varettoni","year":"2013","journal-title":"Leukemia Lymphoma"},{"issue":"May (18)","key":"10.1016\/j.semcancer.2013.09.001_bib0565","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1182\/blood-2010-11-316737","article-title":"Evidence of canonical somatic hypermutation in hairy cell leukemia","volume":"117","author":"Arons","year":"2011","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/10428194.2010.530362","article-title":"Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis","volume":"52","author":"Forconi","year":"2011","journal-title":"Leukemia Lymphoma"},{"issue":"June (6)","key":"10.1016\/j.semcancer.2013.09.001_bib0575","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/10428190801947559","article-title":"Molecular genetic characterization reveals new subsets of mantle cell lymphoma","volume":"49","author":"Thelander","year":"2008","journal-title":"Leukemia Lymphoma"},{"issue":"October (43)","key":"10.1016\/j.semcancer.2013.09.001_bib0580","doi-asserted-by":"crossref","first-page":"18587","DOI":"10.1073\/pnas.1009388107","article-title":"Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins","volume":"107","author":"Coelho","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March (3)","key":"10.1016\/j.semcancer.2013.09.001_bib0585","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","article-title":"Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma","volume":"204","author":"Lenz","year":"2007","journal-title":"J Exp Med"},{"issue":"February (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0590","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMcibr067155","article-title":"A closer look at follicular lymphoma","volume":"356","author":"Staudt","year":"2007","journal-title":"N Engl J Med"},{"issue":"October (8)","key":"10.1016\/j.semcancer.2013.09.001_bib0595","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood.V92.8.2871","article-title":"DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma","volume":"92","author":"Vaandrager","year":"1998","journal-title":"Blood"},{"issue":"November (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0600","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/intimm\/dxq441","article-title":"Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses","volume":"22","author":"Zuckerman","year":"2010","journal-title":"Int Immunol"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0605","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"June (7247)","key":"10.1016\/j.semcancer.2013.09.001_bib0610","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"February (4)","key":"10.1016\/j.semcancer.2013.09.001_bib0615","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood.V99.4.1398","article-title":"BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression","volume":"99","author":"Maes","year":"2002","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0620","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0092-8674(00)80957-5","article-title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types","volume":"96","author":"Willis","year":"1999","journal-title":"Cell"},{"issue":"June (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0625","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0835","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-11-0467","article-title":"MALT1 protease: a new therapeutic target in B lymphoma and beyond?","volume":"17","author":"McAllister-Lucas","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"January (9249)","key":"10.1016\/j.semcancer.2013.09.001_bib0840","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","article-title":"Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy","volume":"357","author":"Liu","year":"2001","journal-title":"Lancet"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0845","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.2005.081117","article-title":"Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H. pylori eradication","volume":"55","author":"Ye","year":"2006","journal-title":"Gut"},{"issue":"October (7418)","key":"10.1016\/j.semcancer.2013.09.001_bib0630","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"August (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0635","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"issue":"October (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0640","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1084\/jem.20091962","article-title":"Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases","volume":"207","author":"Miletic","year":"2010","journal-title":"J Exp Med"},{"issue":"November (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0645","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","article-title":"PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma","volume":"21","author":"Abubaker","year":"2007","journal-title":"Leukemia"},{"issue":"September (36)","key":"10.1016\/j.semcancer.2013.09.001_bib0650","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"October (10)","key":"10.1016\/j.semcancer.2013.09.001_bib0655","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cellsig.2012.06.009","article-title":"Activation of PI3K\/Akt signaling by n-terminal SH2 domain mutants of the p85alpha regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain","volume":"24","author":"Hofmann","year":"2012","journal-title":"Cell Signal"},{"issue":"January (2)","key":"10.1016\/j.semcancer.2013.09.001_bib0660","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"September (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0665","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"September (12)","key":"10.1016\/j.semcancer.2013.09.001_bib0670","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"September (13)","key":"10.1016\/j.semcancer.2013.09.001_bib0675","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"March (13)","key":"10.1016\/j.semcancer.2013.09.001_bib0680","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"June (12)","key":"10.1016\/j.semcancer.2013.09.001_bib0685","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0690","first-page":"55","article-title":"CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"116","author":"Furman","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"August (23)","key":"10.1016\/j.semcancer.2013.09.001_bib0695","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0700","first-page":"191","volume":"120","author":"Coutre","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"May (15_suppl)","key":"10.1016\/j.semcancer.2013.09.001_bib0705","first-page":"6518","article-title":"A phase I\/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)","volume":"30","author":"Furman","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"May (22)","key":"10.1016\/j.semcancer.2013.09.001_bib0710","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","article-title":"Isoform-selective phosphoinositide 3\u2032-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach","volume":"113","author":"Niedermeier","year":"2009","journal-title":"Blood"},{"issue":"April (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0715","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-11-2113","article-title":"ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K\/AKT inhibition and induction of oxidative stress","volume":"18","author":"Chapman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0720","first-page":"2683","article-title":"Phase I trial of SAR245408 (S08), a pan-phosphatidylinositol 3 kinase (PI3K) inhibitor, in patients with chronic lymphocytic leukemia (CLL) and lymphoma","volume":"118","author":"Brown","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0725","first-page":"3914","article-title":"Comparison of the PI3K-{delta} inhibitors TGR1202 and GS-1101 in inducing cytotoxicity and inhibiting phosphorylation of Akt in CLL cells in vitro","volume":"120","author":"Friedman","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0730","first-page":"2907","article-title":"Preclinical characterization of PWT143, a novel selective and potent phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor with ex-vivo activity in hematologic malignancies","volume":"120","author":"O\u2019Farrell","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"May (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0735","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.semcancer.2013.09.001_bib0740","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"June","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0785","first-page":"686","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study","volume":"120","author":"Wilson","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2013.09.001_bib0745","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"March (11)","key":"10.1016\/j.semcancer.2013.09.001_bib0750","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.09.001_bib0755","article-title":"In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients","author":"Herman","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"June (23)","key":"10.1016\/j.semcancer.2013.09.001_bib0760","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"February (5)","key":"10.1016\/j.semcancer.2013.09.001_bib0765","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0770","first-page":"2569","article-title":"Activity of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in B-cell acute lymphoblastic leukemia (B-ALL)","volume":"120","author":"Kim","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0775","first-page":"1802","article-title":"Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) blocks hairy cell leukemia (HCL) survival, proliferation, and BCR signaling: a new therapeutic approach for HCL","volume":"120","author":"Sivina","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0780","first-page":"156","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma","volume":"120","author":"Fowler","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"June (S1)","key":"10.1016\/j.semcancer.2013.09.001_bib0790","first-page":"96","article-title":"Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukemia patients with 17p deletion","volume":"31","author":"Wiestner","year":"2013","journal-title":"Hematol Oncol"},{"issue":"May (15_suppl)","key":"10.1016\/j.semcancer.2013.09.001_bib0795","first-page":"6508","article-title":"A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","volume":"30","author":"Jaglowski","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"May (15_suppl)","key":"10.1016\/j.semcancer.2013.09.001_bib0800","first-page":"6515","article-title":"Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)\/rituximab (R) (BR) in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib\/II study","volume":"30","author":"O\u2019Brien","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0805","first-page":"187","article-title":"The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients","volume":"120","author":"Burger","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"May (15_suppl)","key":"10.1016\/j.semcancer.2013.09.001_bib0810","first-page":"8032","article-title":"Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)","volume":"30","author":"Brown","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"June (s1)","key":"10.1016\/j.semcancer.2013.09.001_bib0815","first-page":"217","article-title":"Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed\/refractory chronic lymphocytic leukemia (CLL) and B-cell Non-Hodgkin lymphoma (B-NHL)","volume":"98","author":"Brown","year":"2013","journal-title":"Haematologica"},{"issue":"July (7)","key":"10.1016\/j.semcancer.2013.09.001_bib0820","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/13543784.2012.685650","article-title":"Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders","volume":"21","author":"Robak","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"issue":"November (21)","key":"10.1016\/j.semcancer.2013.09.001_bib0825","first-page":"1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"116","author":"Kahl","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.semcancer.2013.09.001_bib0830","author":"Byrd","year":"2012","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X13000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X13000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:05:02Z","timestamp":1715994302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X13000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":170,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1044579X13000886"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2013.09.001","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell receptor signaling as a driver of lymphoma development and evolution","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2013.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}